Evidence-Based Cannabis for Dementia-Related Behavioral Agitation
A meta-analysis of 10 RCTs shows medical cannabis can reduce dementia-related agitation—a behavioral symptom that devastates both patients and caregivers. Cannabinoids showed effectiveness comparable to antipsychotics but with a safer profile, especially…
Efficacy and Safety of Cannabinoids for Neuropsychiatric Symptoms of Dementia: A Systematic Review with Meta-analysis.
This systematic review evaluates cannabinoid efficacy dementia symptoms including agitation, anxiety, and depression in patients with dementia. It highlights cannabinoids as a potential safer alternative to traditional antipsychotics. The study…
Cannabis-Based Spray Shown Feasible and Safe for Alzheimer’s Agitation in UK Care Homes
The nabiximols Alzheimer agitation trial demonstrated that administering this cannabis-based spray is feasible and safe for patients in UK care homes. Despite challenges, the study showed perfect adherence and no adverse drug reactions. These results…
Cannabis-Based Spray Shows Early Safety Promise for Alzheimer’s Agitation—But Proof of Efficacy Still Awaited
The nabiximols oromucosal spray feasibility trial demonstrated safe administration in Alzheimer's patients with agitation. Despite challenges, the study showed full adherence and no adverse reactions. These findings support larger trials to evaluate…
Assessment of Clinical Factors Predicting Nabilone Response for Agitation in Alzheimer’s
This study investigates nabilone response predictors in treating agitation in Alzheimer's disease. Researchers analyzed clinical factors influencing treatment outcomes. Understanding these predictors may guide personalized cannabinoid therapy for…